Thus, the SELECT trial exceeded expectations (many commentators predicted the topline reduction to be likely sub-20%), but also underlined the need for further outcomes trials to clarify other potential benefits, as well as, for competitors, meeting or exceeding the performance of Wegovy
To view a copy of this licence, visit About this article Cite this article Ko, SH., Cho, KA., Li, X
GLP-1 Clarification: OzemPatches is not a GLP-1 medication
doi: 10.14309/ctg.0000000000000273 Koch DG, Speiser JL, Durkalski V, et al
About this article Cite this article Llach, CD., Badulescu, S., Tabassum, A
There are some skin conditions that may improve after starting a GLP-1, like psoriasis and hidradenitis suppurativa